Department of Clinical Oncology, Zealand University Hospital Roskilde and Naestved, Roskilde; Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Oncology Supportive Care Consultant, Overland Park, USA.
ESMO Open. 2024 Feb;9(2):102195. doi: 10.1016/j.esmoop.2023.102195. Epub 2024 Jan 11.
• Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics. • The guideline covers emetic risk classification, prevention and management of treatment-induced nausea and vomiting. • The Consensus Committee consisted of 34 multidisciplinary, health care professionals and three patient advocates. • Recommendations are based on evidence-based data (level of evidence) and the authors’ collective expert opinion (grade). • All recommendations are for the first course of antineoplastic therapy; modifications may be needed in subsequent courses.
• 恶心和呕吐被认为是接受抗肿瘤治疗的患者最麻烦的不良反应之一。 • 该指南涵盖了致吐风险分类、预防和处理治疗引起的恶心和呕吐。 • 共识委员会由 34 名多学科医疗保健专业人员和 3 名患者权益倡导者组成。 • 建议基于基于证据的数据（证据水平）和作者的集体专家意见（等级）。 • 所有建议均适用于抗肿瘤治疗的第一疗程；后续疗程可能需要进行修改。
